Evidence map›Paper›PMID 36525443›Full record

ArticlePloS one2022

Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak.

Antoine Oloma Tshomba, Daniel-Ricky Mukadi-Bamuleka, Anja De Weggheleire, Olivier M Tshiani, Richard O Kitenge, Charles T Kayembe, Bart K M Jacobs, Lutgarde Lynen, Placide Mbala-Kingebeni, Jean-Jacques Muyembe-Tamfum and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Antoine Oloma TshombaDepartment of Public Health, University of Kisangani, Kisangani, Democratic Republic of Congo.ORCID 0000-0003-2440-8468
Daniel-Ricky Mukadi-BamulekaNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Anja De WeggheleireDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-9377-4766
Olivier M TshianiNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Richard O KitengeNational Emergency Program, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Charles T KayembeDepartment of Internal Medicine, University of Kisangani, Kisangani, Democratic Republic of the Congo.
Bart K M JacobsDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Lutgarde LynenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-7183-4895
Placide Mbala-KingebeniNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Jean-Jacques Muyembe-TamfumNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Steve Ahuka-MundekeNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Dieudonné N MumbaNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0002-5886-2004
Désiré D Tshala-KatumbayNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Sabue MulanguNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
University of Kinshasa · CDInstituut voor Tropische Geneeskunde · BEMinistry of Public Health · CDNational Institute of Biomedical Research · CDOregon Health & Science University · USUniversité de Kisangani · CD

Funding

NeuroEbolaR01EY031894 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MUMBA, NGOYI, MWANZA, JEAN-CLAUDE · 2021 to 2024
$2.2M
NEI NIH HHS R01 EY031894
6 · The paper itself

Abstract

backgroundThe control of Ebola virus disease (EVD) outbreaks relies on rapid diagnosis and prompt action, a daunting task in limited-resource contexts. This study develops prediction scores that can help healthcare workers improve their decision-making at the triage-point of EVD suspect-cases during EVD outbreaks.

methodsWe computed accuracy measurements of EVD predictors to assess their diagnosing ability compared with the reference standard GeneXpert® results, during the eastern DRC EVD outbreak. We developed predictive scores using the Spiegelhalter-Knill-Jones approach and constructed a clinical prediction score (CPS) and an extended clinical prediction score (ECPS). We plotted the receiver operating characteristic curves (ROCs), estimated the area under the ROC (AUROC) to assess the performance of scores, and computed net benefits (NB) to assess the clinical utility (decision-making ability) of the scores at a given cut-off. We performed decision curve analysis (DCA) to compare, at a range of threshold probabilities, prediction scores' decision-making ability and to quantify the number of unnecessary isolation.

resultsThe analysis was done on data from 10432 subjects, including 651 EVD cases. The EVD prevalence was 6.2% in the whole dataset, 14.8% in the subgroup of suspects who fitted the WHO Ebola case definition, and 3.2% for the set of suspects who did not fit this case definition. The WHO clinical definition yielded 61.6% sensitivity and 76.4% specificity. Fatigue, difficulty in swallowing, red eyes, gingival bleeding, hematemesis, confusion, hemoptysis, and a history of contact with an EVD case were predictors of EVD. The AUROC for ECPS was 0.88 (95%CI: 0.86-0.89), significantly greater than this for CPS, 0.71 (95%CI: 0.69-0.73) (p < 0.0001). At -1 point of score, the CPS yielded a sensitivity of 85.4% and specificity of 42.3%, and the ECPS yielded sensitivity of 78.8% and specificity of 81.4%. The diagnostic performance of the scores varied in the three disease contexts (the whole, fitting or not fitting the WHO case definition data sets). At 10% of threshold probability, e.g. in disease-adverse context, ECPS gave an NB of 0.033 and a net reduction of unnecessary isolation of 67.1%. Using ECPS as a joint approach to isolate EVD suspects reduces the number of unnecessary isolations by 65.7%.

conclusionThe scores developed in our study showed a good performance as EVD case predictors since their use improved the net benefit, i.e., their clinical utility. These rapid and low-cost tools can help in decision-making to isolate EVD-suspicious cases at the triage point during an outbreak. However, these tools still require external validation and cost-effectiveness evaluation before being used on a large scale.

Indexed as

EbolavirusHemorrhagic Fever, EbolaDisease OutbreaksHumansPrevalenceROC CurveTriage

Identifiers

PMID36525443
PMCPMC9757576
OpenAlexW4311651504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.